Latest filing published 28 May 2026 for Bausch & Lomb Corp, €215k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +15.9%Entry US$17.60 · Close 28 Oct 2026 US$20.40
- +126.4%Entry US$14.71 · Close at T+365 US$33.31
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Thomas W. Ross Sr.: trading record in brief
This profile gathers the share dealings of Thomas W. Ross Sr. across 3 companies, led by Bausch & Lomb Corp, Valeant Pharmaceuticals International, Inc. and Bausch Health Companies Inc. Over a trading history stretching from 11 March 2016 to 26 May 2026, the count stands at 20 filings.
Every open-market trade on record is a purchase: 4 purchases worth €258k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 16 share grants. So far in 2026, the count stands at 1 purchase and no sales.
Half of the purchases are above €69k and half below. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 28 May 2026, reports a share grant of €215k in Bausch & Lomb Corp. The latest purchase dates back some time: it was published 250 days ago, on 4 March 2026. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Thomas W. Ross Sr.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,842 shares@ US$15.780.0037% mcap76.0% of flowCommon Shares, No Par ValueSEC:0001860742-26-000081:0
- 4,500 shares0Common Shares, No Par ValueSEC:0001860742-26-000053:1
- 4,500 shares@ US$17.67924.0% of flowCommon Shares, No Par ValueSEC:0001860742-26-000053:0Canonical exit: 1 Jun 2026 (T+90)
- 20,338 shares0Common Shares, No Par ValueSEC:0001127602-25-015806:0
- 14,696 shares0Common Shares, No Par ValueSEC:0001127602-24-021760:0
- 29,205 shares0Common Shares, No Par ValueSEC:0001127602-23-016300:0
- 12,857 shares0Common Shares, No Par ValueSEC:0001127602-23-014713:0
- 34,387 shares0Common Shares, No Par ValueSEC:0001127602-22-018206:0
- 12,500 shares0Common Shares, No Par ValueSEC:0000899243-22-017855:0
- 7,645 shares0Common Shares, No Par ValueSEC:0001127602-21-014916:0
- 11,037 shares0Common Shares, No Par ValueSEC:0001127602-20-015042:0
- 2,500 shares@ US$15.54100.0% of flowCommon Stock, No Par ValueSEC:0001127602-20-010794:0Canonical exit: 10 Jun 2020 (T+90)
- 10,633 shares@ US$23.5186.6% of flowCommon Stock, No Par ValueSEC:0001127602-19-017271:0
- 13,881 shares0Common Stock, No Par ValueSEC:0001127602-18-016656:0
- 14,285 shares0Common Stock, No Par ValueSEC:0001127602-18-016413:0
- 25,406 shares0Common Stock, no par valueSEC:0000885590-17-000026:0
- 5,000 shares@ US$14.7344.5% of flowCommon Stock, no par valueSEC:0001669396-16-000004:0Canonical exit: 14 Mar 2017 (T+90)
- 4,000 shares@ US$24.4055.5% of flowCommon Stock, no par valueSEC:0001669396-16-000003:0Canonical exit: 11 Sept 2016 (T+90)
- 16,726 shares0Common Stock, no par valueSEC:0001669396-16-000001:0
- 1,096 shares0Common Stock, no par valueSEC:0000885590-16-000092:0
20 of 20 declarations
